Europe stocks hit fresh record high on earnings, Ukraine peace hopes

Europe stocks hit fresh record high on earnings, Ukraine peace hopes


European stock markets were broadly higher Thursday, amid a flurry of earnings and economic data and rising hopes of an end to the Russia-Ukraine war.

The regional Stoxx 600 index maintained positive momentum from earlier this week, when it marked three record closing highs, gaining another 0.74% by midday in London to hit another all-time intraday peak.

Markets held onto gains even as investors brace for a new swathe of tariffs to potentially be announced by U.S. President Donald Trump, who posted on social media in the early U.S. hours: “TODAY IS THE BIG ONE: RECIPROCAL TARIFFS!!!”

Those retaliatory duties are expected to hit every country which imposes import duties on the U.S., though exemptions for some sectors are reportedly being considered.

Top posts

  • Nestle full-year sales growth declines in line with expectations, points to uptick in 2025 | view post
  • Commerzbank to cut 3,900 jobs as it unveils new targets | view post
  • Europe must ‘pull back’ on regulation, Siemens CEO says as profits beat expectations | view post
  • UK economy ekes out 0.1% growth in fourth quarter | view post
  • Barclays posts 2024 pretax profit hike, launches £1 billion share buyback | view post

In European markets, German technology conglomerate Siemens was among the top performers, up 5.6% after reporting better than expected first-quarter profits, despite a “significant decline” at its factory automation business.

However, the U.K.’s FTSE 100 dropped 0.58%, weighed down by declines in banking and oil and gas stocks. Shares of British bank Barclays were 5.4% lower, despite the lender posting a slight beat on full-year pre-tax profit and announcing a £1 billion ($1.25 billion) share buyback. Consumer goods giant Unilever was meanwhile down 7% on weaker sales growth figures than forecast.

Investors are also assessing figures from the Office for National Statistics which showed the U.K. economy grew by 0.1% in the fourth quarter, ahead of expectations for a 0.1% contraction.

“Fourth-quarter UK GDP wasn’t as bad as it could have been, though the details weren’t great … all of the increase in GDP across 2024 can be put down to population growth. GDP per capita actually fell slightly across the year,” ING developed markets economist, James Smith, said in a note.

The gains for markets also come as an end to the Ukraine-Russia war becomes a more distinct prospect.

U.S. President Donald Trump said on Wednesday that he had spoken to both Russian President Vladimir Putin and Ukrainian President Volodymyr Zelenskyy, and that both leaders wanted peace. He said he had ordered U.S. officials to begin talks immediately on ending the war.



Source

Fed officials split on where interest rates should go, minutes say
World

Fed officials split on where interest rates should go, minutes say

Divided Federal Reserve officials at their January meeting indicated that further interest rate cuts should be paused for now but could resume later in the year only if inflation cooperates. While the decision to hold the central bank’s benchmark rate steady mostly was met with approval, the path ahead appeared less certain, with members conflicted […]

Read More
Microsoft’s Brad Smith says U.S. tech should ‘worry a little’ about Chinese firms’ government subsidies
World

Microsoft’s Brad Smith says U.S. tech should ‘worry a little’ about Chinese firms’ government subsidies

Microsoft President Brad Smith speaks at a press conference at the Representation of the State of North Rhine-Westphalia about future visions for the development and application of artificial intelligence in education in NRW in Berlin on June 4, 2025. Soeren Stache | Picture Alliance | Getty Images American tech companies should “worry a little bit” […]

Read More
FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal
World

FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal

A researcher works in the lab at the Moderna headquarters in Cambridge, Massachusetts, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna said on Wednesday the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing the agency’s earlier decision to refuse to accept the application in a move […]

Read More